208 related articles for article (PubMed ID: 35263394)
1. Prognostic biomarkers related to tumoral microenvironment in pancreatic ductal adenocarcinoma: a systematic review.
Constantin AL; Cazacu IM; Stroescu C; Copăescu C; Săftoiu A
Rom J Morphol Embryol; 2021; 62(3):671-678. PubMed ID: 35263394
[TBL] [Abstract][Full Text] [Related]
2. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Mahajan UM; Langhoff E; Goni E; Costello E; Greenhalf W; Halloran C; Ormanns S; Kruger S; Boeck S; Ribback S; Beyer G; Dombroswki F; Weiss FU; Neoptolemos JP; Werner J; D'Haese JG; Bazhin A; Peterhansl J; Pichlmeier S; Büchler MW; Kleeff J; Ganeh P; Sendler M; Palmer DH; Kohlmann T; Rad R; Regel I; Lerch MM; Mayerle J
Gastroenterology; 2018 Nov; 155(5):1625-1639.e2. PubMed ID: 30092175
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic ultrasound-guided fine-needle biopsy as a tool for studying the intra-tumoral microbiome in pancreatic ductal adenocarcinoma: a pilot study.
Chu CS; Yang CY; Yeh CC; Lin RT; Chen CC; Bai LY; Hung MC; Lin CC; Wu CY; Lin JT
Sci Rep; 2022 Jan; 12(1):107. PubMed ID: 34997106
[TBL] [Abstract][Full Text] [Related]
4. Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
McGuigan AJ; Coleman HG; McCain RS; Kelly PJ; Johnston DI; Taylor MA; Turkington RC
J Pathol Clin Res; 2021 Mar; 7(2):99-112. PubMed ID: 33481339
[TBL] [Abstract][Full Text] [Related]
5. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens.
Rasmussen LG; Verbeke CS; Sørensen MD; Pfeiffer P; Tan Q; Mortensen MB; Fristrup C; Detlefsen S
Pancreatology; 2021 Apr; 21(3):530-543. PubMed ID: 33637450
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic ultrasound may be used to deliver gene expression signatures using digital mRNA detection methods to immunophenotype pancreatic ductal adenocarcinoma to facilitate personalized immunotherapy.
Gleeson FC; Levy MJ; Jackson RA; Murphy SJ; Halling KC; Kipp BR; Graham RP; Zhang L
Pancreatology; 2020 Mar; 20(2):229-238. PubMed ID: 31831392
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
9. Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population.
Maehira H; Miyake T; Iida H; Tokuda A; Mori H; Yasukawa D; Mukaisho KI; Shimizu T; Tani M
Ann Surg Oncol; 2019 Dec; 26(13):4791-4804. PubMed ID: 31583548
[TBL] [Abstract][Full Text] [Related]
10. Role of Maspin, CK17 and Ki-67 Immunophenotyping in Diagnosing of Pancreatic Ductal Adenocarcinoma in Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytology.
Mamdouh MM; Okasha H; Shaaban HAM; Hafez NH; El-Gemeie EH
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3299-3307. PubMed ID: 34711007
[TBL] [Abstract][Full Text] [Related]
11. Interobserver agreement and accuracy of preoperative endoscopic ultrasound-guided biopsy for histological grading of pancreatic cancer.
Larghi A; Correale L; Ricci R; Abdulkader I; Monges G; Iglesias-Garcia J; Giovannini M; Attili F; Vitale G; Hassan C; Costamagna G; Rindi G
Endoscopy; 2015 Apr; 47(4):308-14. PubMed ID: 25521572
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Liu Q; Cui M; Wang M; Hua S; Gao J; Liao Q
Front Immunol; 2021; 12():774435. PubMed ID: 35046938
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers.
Mi H; Sivagnanam S; Betts CB; Liudahl SM; Jaffee EM; Coussens LM; Popel AS
Cancer Res; 2022 Dec; 82(23):4359-4372. PubMed ID: 36112643
[TBL] [Abstract][Full Text] [Related]
14. Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next-generation sequencing acquired by endoscopic ultrasound-guided FNA and FNB.
Gan Q; Roy-Chowdhuri S; Duose DY; Stewart JM; Coronel E; Bhutani MS; Lee JH; Weston B; Ge PS; Ross WA; Maitra A
Cancer Cytopathol; 2022 Apr; 130(4):275-283. PubMed ID: 34905283
[TBL] [Abstract][Full Text] [Related]
15. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
[TBL] [Abstract][Full Text] [Related]
16. EGFR Mutated Lung Adenocarcinoma Metastasis to the Pancreas Mimicking Primary Pancreatic Ductal Carcinoma.
Cao C; Kong MX; Kapali M; Moezardalan K; Shi Q; Azarm A; Lai J
Anticancer Res; 2020 Aug; 40(8):4401-4404. PubMed ID: 32727769
[TBL] [Abstract][Full Text] [Related]
17. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of MMR Status and PD-L1 Expression Using Specimens Obtained by EUS-FNB in Patients with Pancreatic Ductal Adenocarcinoma (PDAC).
Constantin A; Iovănescu V; Cazacu IM; Ungureanu BS; Copăescu C; Stroescu C; Bejinariu N; Săftoiu A
Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204385
[TBL] [Abstract][Full Text] [Related]
19. [Pathological features related to onco-immunity and their clinical significance of pancreatic ductal adenocarcinoma].
Wang CM; Xu CY; Jiang S; Zhou Q; Jiang ZJ; Cheng GP; Wu MJ; Feng TT; Yin WJ
Zhonghua Bing Li Xue Za Zhi; 2022 May; 51(5):419-424. PubMed ID: 35511637
[No Abstract] [Full Text] [Related]
20. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
